Leaderboards/SARS-CoV-2 and COVID-19 Research

SARS-CoV-2 and COVID-19 Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Bo Meng
University of Cambridge
2
Sahil Loomba
Imperial College London
3
Angélica Jayk Bernal
Unknown
4
Moriah Bergwerk
Tel Aviv University
5
Rita E. Chen
Washington University in St. Louis
6
Panke Qu
The Ohio State University
7
Prabhu S. Arunachalam
Stanford University
8
Shruti Khare
Agency for Science, Technology and Research
9
Dhiraj Mannar
University of British Columbia
10
Julio S. Solís Arce
WZB Berlin Social Science Center

Papers

1
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
Cell|2024
159 cit.
2
Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein
Nature Communications|2024
20 cit.
3
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates
Science Translational Medicine|2024
10 cit.
4
Hypoxia drives HIF2-dependent reversible macrophage cell cycle entry
Cell Reports|2024
5 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Yu-Ling Zhang
Shanghai Public Health Clinical Center
2
Davide Corti
Vir Biotechnology (Switzerland)
3
Kwok-Yung Yuen
Hong Kong Baptist University
4
Peter Zuidewind
Stellenbosch University
5
Xiangxi Wang
Peking University
6
Yuanyuan Zhang
Westlake University
7
John H. Beigel
National Institute of Allergy and Infectious Diseases
8
Daniela Weiskopf
Federal Office for Radiation Protection
9
Lei Liu
Hunan Agricultural University
10
Timothée Bruel
Institut Pasteur

Papers

1
Homologous and Heterologous Covid-19 Booster Vaccinations
New England Journal of Medicine|2022
618 cit.
2
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cell|2022
470 cit.
3
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Nature Medicine|2022
309 cit.
4
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Nature|2022
195 cit.
5
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
Cell Host & Microbe|2022
188 cit.
6
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
Cell Reports Medicine|2022
58 cit.
7
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Protein & Cell|2024
41 cit.
8
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
Nature Communications|2022
32 cit.
9
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV|2022
31 cit.
10
Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity
National Science Review|2024
30 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Wenjie Tan
Sinopec (China)
2
Nanshan Zhong
State Key Laboratory of Respiratory Disease
3
Stefan Pöhlmann
German Primate Center
4
Zheng‐Li Shi
Chinese Academy of Sciences
5
Jianwei Wang
Zhejiang Cancer Hospital
6
Kwok‐Yung Yuen
University of Hong Kong - Shenzhen Hospital
7
David Veesler
Howard Hughes Medical Institute
8
Bin Cao
Shandong Provincial Hospital
9
William C. Gruber
Pfizer (United States)
10
Ralph S. Baric
University of North Carolina at Chapel Hill

Papers

1
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
The Lancet|2020
51.8k cit.
2
Clinical Characteristics of Coronavirus Disease 2019 in China
New England Journal of Medicine|2020
31.2k cit.
3
A Novel Coronavirus from Patients with Pneumonia in China, 2019
New England Journal of Medicine|2020
30.4k cit.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
The Lancet|2020
29.1k cit.
5
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Nature|2020
23.3k cit.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Cell|2020
21.4k cit.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine|2020
15.5k cit.
8
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
The Lancet|2020
12.6k cit.
9
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Cell|2020
9.1k cit.
10
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
New England Journal of Medicine|2020
5.5k cit.

Reagents for SARS-CoV-2 and COVID-19 Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Thermo Fisher ScientificEvidence 73

CD2 Monoclonal Antibody (S5.5), FITC

Cited in 36 papers
#CD0201-4
View Evidence →
Thermo Fisher ScientificEvidence 79

CD64 Monoclonal Antibody (10.1), PE

Cited in 36 papers
#CD6404-4
View Evidence →
Cell Signaling TechnologyEvidence 63

Phospho-FAK (Tyr397) Matched Antibody Pair

Cited in 33 papers
#40143$1,675
View Evidence →

🌟 All-Time

Most validated

R&D SystemsEvidence 60

Human/Mouse/Rat/Hamster ACE-2 Antibody

Cited in 40 papers
#AF933 (also AF933-SP)
View Evidence →
Thermo Fisher ScientificEvidence 77

CD28 Monoclonal Antibody (10F3)

Cited in 36 papers
#CD2800-4
View Evidence →
Thermo Fisher ScientificEvidence 78

CD61 Monoclonal Antibody (F11), PE

Cited in 36 papers
#CD6104-4
View Evidence →